Red X iconGreen tick iconYellow tick icon
Microsoft outage The University of Otago is impacted by the issues affecting Microsoft services globally. We are operating as usual, but be aware we are not receiving emails. Please call 0800 80 80 98 if you need to contact the University urgently. Find out more

Barry HockScientific Officer
Honorary Research Fellow

BSc(Hons), PhD(Otago)

Email barry.hock@otago.ac.nz
Tel +64 3 244 1106

Publications

Gieseg, S., Hock, B., Ogugofor, M., & McCormick, S. (2026). Could chimeric antigen receptor-T cell treatment of atherosclerosis in mice translate to a human therapy? Annals of Translational Medicine, 14(4). Advance online publication. doi: 10.21037/atm-2026-0132 Journal - Research Other

Dobson, L. J., Marron, P. W., Drabble, A. H. T., Liyanage, T. D., Pe, K. C., Slaney, C. Y., Hock, B. D., & McLellan, A. D. (2026). Parallel processing of T cells and natural killer cells to enhance in vivo CAR T cell activity against blood and solid cancers. Clinical & Translational Immunology, 15(9), e70120. doi: 10.1002/cti2.70120 Journal - Research Article

Topham, B. J., Hock, B. D., Wiggins, G. A. R., Ashby, L. V., Magon, N. J., Phillips, E., Symonds, E. K. C., Danielson, K. M., & Currie, M. J. (2026). Priming of human monocytes by β-glucan and obesity-associated factors: Modifications to global DNA methylation, gene expression, phenotype and function. Frontiers in Immunology, 17, 1825431. doi: 10.3389/fimmu.2026.1825431 Journal - Research Article

Dobson, L. J., Hock, B. D., Drabble, A. H. T., Goddard, L., McKenzie, J. L., MacPherson, S. A., & McLellan, A. D. (2026). Enhanced Fc and complement activity of Fc-modified avelumab boosts anti-tumor activity but promotes NK cell fratricide. Clinical & Translational Immunology, 15, e70098. doi: 10.1002/cti2.70098 Journal - Research Article

Hock, B. D., Goddard, L., Dobson, L. J., MacPherson, S. A., O'Donnell, J. L., McKenzie, J. L., & McLellan, A. D. (2025). Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1. Cancer Immunology, Immunotherapy, 74, 216. doi: 10.1007/s00262-025-04078-0 Journal - Research Article

Back to top